NKTX NASDAQ
Nkarta, Inc.
1W: -2.3%
1M: -36.3%
3M: -20.2%
YTD: -15.4%
1Y: -15.0%
3Y: +4.3%
5Y: -93.8%
$1.70
-0.13 (-7.10%)
Pre-Market: $1.72 (+0.02, +0.88%)
Weekly Expected Move ±6.1%
$2
$2
$2
$2
$2
Credit Risk of going bust: higher than 83% of companies Debt: 37.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 93%), Nkarta, Inc. would be worth roughly what it owes.
Total debt $73.5M against a stock market value of $121.8M.
Distance to default 2.35 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.8M (short-term plus half of long-term), stock volatility 73.0%; Altman Z'' -3.16. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.12 (down 93%), Nkarta, Inc. would be worth roughly what it owes.
Total debt $73.5M against a stock market value of $121.8M.
Distance to default 2.35 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.8M (short-term plus half of long-term), stock volatility 73.0%; Altman Z'' -3.16. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$121.8M
52W Range1.58-3.72
Volume2,523,106
Avg Volume724,441
Beta0.94
Dividend—
Analyst Ratings
Company Info
CEOPaul J. Hastings
Employees106
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-10
Websitenkartatx.com
1150 Veterans Boulevard
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
415 582 4923
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Latest News
Nkarta Inc. NKTX - Phase 1 Results November - Positive Endpoints to be Met
Nkarta, Inc. - Positive Poster Presentation - Debt Free - FDA Support
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HASTINGS PAUL J | S-Sale | 1,776 | $2.71 | 2026-06-18 |
| Vratsanos George | A-Award | 37,000 | $2.46 | 2026-06-10 |
| Scheiner Zachary | A-Award | 37,000 | $2.46 | 2026-06-10 |
| PATTERSON LEONE D | A-Award | 37,000 | $2.46 | 2026-06-10 |
| Dybbs Michael | A-Award | 37,000 | $2.46 | 2026-06-10 |